Streetbeat News

Revenues

FOLD

Amicus Therapeutics has raised its FY24 sales outlook, with total revenue now expected to grow between 26% to 31%, and Galafold revenue growth adjusted to 14% to 18%. The updated sales outlook is $503.19M-$523.16M, compared to the previous estimate of $499.195M-$519.163M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:09 am

TGLS

Tecnoglass has raised its FY24 revenue outlook to $860M-$910M from $875M, and adjusted EBITDA to $260M-$285M from $267M, surpassing the $874.99M estimate.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:09 am

TTSH

Tile Shop Holdings (NASDAQ:TTSH) reported a significant decline in its Q2 earnings and sales compared to the same period last year. The company's EPS dropped by 75% from $0.12 to $0.03, and sales decreased by 7.28% from $98.56 million to $91.38 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:09 am

SN

SharkNinja (NYSE:SN) reported Q2 2024 adjusted EPS of $0.71, beating the analyst estimate of $0.62. The company also reported sales of $1.249 billion, surpassing the $1.089 billion estimate and marking a 31.43% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:08 am

COLD

Americold Realty Trust (NYSE:COLD) reported Q2 2024 earnings per share (EPS) of $0.33, beating the analyst consensus estimate of $0.28 by 17.86%. However, the company's quarterly sales of $660.955 million slightly missed the estimate of $661.984 million by 0.16%. This represents a 1.75% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:08 am

IRWD

Ironwood Pharmaceuticals has revised its FY 2024 financial guidance due to continued pricing pressure on Linzess, driven by higher-than-expected Medicaid utilization trends. The company now expects sales of $350M-$375M, down from the prior range of $405M-$425M and below the consensus of $410.05M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:08 am

ROIV

Roivant Sciences (NASDAQ:ROIV) reported Q1 2025 adjusted EPS of $(0.17), beating the $(0.26) estimate, and sales of $55.132M, surpassing the $31.500M estimate. This represents a 154.96% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:08 am

LCUT

Lifetime Brands has provided its financial guidance for FY24, projecting adjusted EPS between $0.69 and $0.78, compared to the estimated $0.74. The company also expects sales to range from $690 million to $730 million, against the estimated $705.710 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:07 am

FOLD

Amicus Therapeutics (NASDAQ:FOLD) reported Q2 2024 adjusted EPS of $0.06, significantly beating the analyst estimate of $(0.06). The company also reported sales of $126.669 million, surpassing the $121.244 million estimate. This represents a 185.71% increase in EPS and a 34.04% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:07 am

NRG

NRG Energy reported Q2 sales of $6.659 billion, missing the analyst consensus estimate of $8.320 billion by 19.96%. Despite the miss, sales increased by 4.90% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:06 am